Biohaven Historical Cash Flow
| BHVN Stock | USD 46.01 0.47 1.01% |
Analysis of Biohaven Pharmaceutical cash flow over time is an excellent tool to project Biohaven Pharmaceutical future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 27.3 M or Change In Working Capital of 25.8 M as it is a great indicator of Biohaven Pharmaceutical ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Biohaven Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biohaven Pharmaceutical is a good buy for the upcoming year.
Biohaven |
About Biohaven Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Biohaven balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Biohaven's non-liquid assets can be easily converted into cash.
Biohaven Pharmaceutical Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Biohaven Pharmaceutical to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Biohaven Pharmaceutical operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Biohaven Pharmaceutical financial statement analysis. It represents the amount of money remaining after all of Biohaven Pharmaceutical Holding operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Biohaven Pharmaceutical's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Biohaven Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. At this time, Biohaven Pharmaceutical's Change In Working Capital is very stable compared to the past year. As of the 3rd of December 2024, Total Cash From Financing Activities is likely to grow to about 354.4 M, while Change In Cash is likely to drop about 9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 938K | 41.1M | 3.0M | 2.9M | Other Non Cash Items | 4.5M | 106.3M | 16.1M | 15.3M |
Biohaven Pharmaceutical cash flow statement Correlations
Click cells to compare fundamentals
Biohaven Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biohaven Pharmaceutical cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 53.5M | 73.6M | (6.4M) | 165.5M | 9.5M | 9.0M | |
| Stock Based Compensation | 55.0M | 29.5M | 65.6M | 193.6M | 28.8M | 27.3M | |
| Free Cash Flow | (379.9M) | (78.7M) | (146.8M) | (338.8M) | (334.8M) | (351.5M) | |
| Change In Working Capital | 3.3M | 9.0M | 1.7M | (28.6M) | 24.6M | 25.8M | |
| Begin Period Cash Flow | 264.2M | 9.9M | 83.5M | 77.1M | 242.6M | 130.8M | |
| Other Cashflows From Financing Activities | 434.6M | 152.2M | 138.4M | 483.8M | (31.3M) | (29.8M) | |
| Other Non Cash Items | 93.2M | 4.2M | 4.5M | 106.3M | 16.1M | 15.3M | |
| Capital Expenditures | 2.5M | 2.7M | 938K | 41.1M | 3.0M | 2.9M | |
| Total Cash From Operating Activities | (377.3M) | (76.0M) | (145.8M) | (297.7M) | (331.7M) | (348.3M) | |
| Net Income | (528.8M) | (118.7M) | (213.8M) | (570.3M) | (408.2M) | (428.6M) | |
| Total Cash From Financing Activities | 434.6M | 152.2M | 138.4M | 767.6M | 211.9M | 354.4M | |
| End Period Cash Flow | 317.7M | 83.5M | 77.1M | 242.6M | 252.1M | 215.1M |
Pair Trading with Biohaven Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biohaven Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biohaven Stock
| 0.88 | VCNX | Vaccinex | PairCorr |
| 0.46 | DRMA | Dermata Therapeutics | PairCorr |
| 0.45 | VALN | Valneva SE ADR | PairCorr |
| 0.34 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Biohaven Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biohaven Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biohaven Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biohaven Pharmaceutical Holding to buy it.
The correlation of Biohaven Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biohaven Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biohaven Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biohaven Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.37) | Return On Assets (1.19) | Return On Equity (2.65) |
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.